Biotech entity
All 1 tracked stories fall under one category: pharma. ClearPoint Neuro is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Danilo D’Alessandro appears in 1 tracked Biotech story from March 18, 2026. The tracked stories average 2 original sources each.
Last mentioned: Mar 18, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: pharma. ClearPoint Neuro is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Danilo D’Alessandro appears in 1 tracked Biotech story from March 18, 2026. The tracked stories average 2 original sources each.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 18 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Danilo D’Alessandro. Shared-story counts are live from our verified record — not editorial picks.
ClearPoint Neuro (CLPT) achieved record full-year 2025 revenue of $37 million, driven by a 23% fourth-quarter surge in its Biologics and Drug Delivery segment. The company is pivoting toward a higher-growth profile through the integration of Eris Holdings and IRRAS, setting an ambitious revenue target of up to $56 million for 2026.
Danilo D’Alessandro is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
